Clicky

Mithra Pharmaceuticals SA(MITRA)

Description: Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.


Keywords: Drugs Breast Cancer Osteoporosis Hormones Hepatotoxins Vagina Phenols Medroxyprogesterone Acetate Contraception Estranes Hormonal Contraception Progestogens Sex Hormones Sterile Injectable Products

Home Page: www.mithra.com

Rue Saint-Georges 5
Liège, 4000
Belgium
Phone: 32 4 349 28 22


Officers

Name Title
Mr. Leon Van Rompay Chief Exec. Officer
Mr. Christophe Marechal Chief Financial Officer
Dr. Graham K. Dixon Ph.D. Chief Scientific Officer
Mr. Benoit Mathieu Group Investor Relations Mang.
Mr. Cedric Darcis Chief Legal Officer
Fanny Storms Compliance Officer
Ms. Maud Vanderthommen Group Communication Mang.
Ms. Laurence Schyns Chief HR Officer
Mr. Jean-Manuel Fontaine Chief Commercial & External Affairs Officer
Prof. Jean-Michel Foidart M.D., Ph.D. Pres of the Scientific Advisory Board & Exec. Director

Exchange: BR

Country: BE

Currency: Euro (€)

Forward PE: 1.3161
Trailing PE: 0
Price-to-Book MRQ: 5.8702
Price-to-Sales TTM: 9.9507
IPO Date:
Fiscal Year End: December
Full Time Employees: 300
Back to stocks